PRP-2019 Adjuvant Antibiotic Technology

Unlocking Strategies to Combat Bacterial Resistance to Antibiotics

Transmission electron microscopy reveals multi drug-resistant P.aeruginosa membrane lysis when exposed to a combination of adjuvant antibiotic and commercial ciprofloxacin. © Polyamyna


Managing infectious diseases has become an escalating global challenge, largely attributed to the emergence and rapid dissemination of antibiotic resistance among pathogenic microorganisms. The 2016–2017 report by the WHO’s Global Antimicrobial Surveillance System (GLASS) underscored this issue across various regions worldwide, revealing widespread multi-drug resistance in diverse infectious agents.

Consequently, a rising number of infections are proving difficult, if not impossible, to treat, resulting in elevated morbidity and mortality rates. Urgent action is imperative to develop new antibiotics. However, conventional drug discovery and development pipelines have made limited strides in yielding novel therapeutics capable of effectively combating these emergent pathogens.

Know More


Strategy for Antibiotic Development


The strategy involves not only discovering new antibiotics but also revitalizing existing ones.

Adjuvants Development


Adjuvants are being developed to enhance the effectiveness of antibiotics.

Polyamyna's Lead Molecules


Polyamyna has identified and refined lead molecules that can overcome bacterial resistance across various antibiotic classes.



These compounds have undergone rigorous validation, showing potent adjuvant activity against antibiotic-resistant bacteria in both laboratory (in-vitro) and worm model (in-vivo) studies.

Antimicrobial Peptide PRP-2019


Evaluation of PRP-2019 revealed its efficacy in clearing multi-drug resistant E.coli infections in Galleria mellonella infection models when combined with Erythromycin, which the pathogen was resistant to.

Promising Potential


This innovation shows promising potential for treating infections caused by antibiotic-resistant bacteria by combining these adjuvant compounds with antibiotics.

Repurposing Discontinued Drugs


These compounds also hold promise for repurposing and rejuvenating discontinued drugs that have become ineffective against antibiotic-resistant infections.


Co-administration with antibiotics to combat drug-resistant bacteria.


A = PBS ,
B = E1225 + PBS ,
C = E1225 + Erythromycin 12.5 mg/kg ,
D = E1225 + Erythromycin 12.5 mg/kg + PRP-2019 7.5 mg/Kg
Percentage survivability of the Galleria mellonella worm model with antibiotic erythromycin and against E. coli E1255 to evaluate the efficacy of PRP – 2019. Data shows the survivability at 24 hours after treatment in percentage. Average percent survival with standard deviation of three independent experiments are reported here. Significant difference between erythromycin alone or in combination with PSB 2019 are indicated by ** (P value≤0.05). Kaplan Meier graph showing one of the three replicates that includes monotherapy.